Benchmark downgrades Codexis to 'hold'
An analyst from Benchmark downgraded Codexis (NASDAQ: CDXS) from 'buy' to 'hold' . Prior to this rating, Codexis had 6 buy ratings, 1 hold ratings, and 0 sell ratings. For consensus...
Strong Buy
or
Codexis News & Analysis
-
-
Piper Sandler maintains Codexis at 'overweight' with a price target of $10.00
An analyst from Piper Sandler maintained Codexis (NASDAQ: CDXS) at 'overweight' with a price target of $10.00 from a prior price target of %currency%%price%. Prior to this rating,...
-
TD Cowen maintains Codexis at 'market perform' with a price target of $2.00
An analyst from TD Cowen maintained Codexis (NASDAQ: CDXS) at 'market perform' with a price target of $2.00 from a prior price target of %currency%%price%. Prior to this rating, Codexis...
-
Codexis earnings missed by $0.18, revenue fell short of estimates
Investing.com - Codexis (NASDAQ: CDXS) reported third quarter EPS of $-0.50, $0.18 worse than the analyst estimate of $-0.32. Revenue for the quarter came in at $9.28M versus the consensus...
-
Stifel maintains Codexis at 'buy' with a price target of $5.00
An analyst from Stifel maintained Codexis (NASDAQ: CDXS) at 'buy' with a price target of $5.00 from a prior price target of %currency%%price%. Prior to this rating, Codexis had 6 buy...
-
Codexis earnings beat by $0.05, revenue topped estimates
Investing.com - Codexis (NASDAQ: CDXS) reported second quarter EPS of $-0.17, $0.05 better than the analyst estimate of $-0.22. Revenue for the quarter came in at $21.32M versus the...
-
Jefferies maintains Codexis at 'buy' with a price target of $6.50
An analyst from Jefferies maintained Codexis (NASDAQ: CDXS) at 'buy' with a price target of $6.50 from a prior price target of %currency%%price%. Prior to this rating, Codexis had 7 buy...
-
Codexis Unveils ECO Synthesis Platform
Codexis , Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the unveiling of its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology, a proprietary new...
-
Benchmark maintains Codexis at 'buy' with a price target of $9.00
An analyst from Benchmark maintained Codexis (NASDAQ: CDXS) at 'buy' and a price target of $9.00 from a prior price target of %currency%%price%. Prior to this rating, Codexis had 8 buy...
-
H.C. Wainwright downgrades Codexis to 'neutral'
An analyst from H.C. Wainwright downgraded Codexis (NASDAQ: CDXS) from Buy to 'neutral' . Prior to this rating, Codexis had 8 buy ratings, 0 hold ratings, and 0 sell ratings. For consensus...
-
Codexis earnings missed by $0.04, revenue fell short of estimates
Investing.com - Codexis (NASDAQ: CDXS) reported first quarter EPS of $-0.34, $0.04 worse than the analyst estimate of $-0.30. Revenue for the quarter came in at $12.98M versus the consensus...
-
Piper Sandler maintains Codexis at Overweight
A Piper Sandler analyst maintained Codexis (NASDAQ: CDXS) at Overweight and a price target of $14.00 from a prior price target of %currency%%price%. Prior to this rating, Codexis had 8...
-
Codexis Announces Decision of Patrick Yang, PhD, Not to Seek Re-Election to Board of Directors
Codexis , Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced that Patrick Yang, PhD, will not seek re-election to the Codexis Board of Directors. Dr. Yang joined...
-
Codexis Tops Q4 EPS by 42c
Codexis (NASDAQ:CDXS) reported Q4 EPS of $0.19, $0.42 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $30.4 million versus the consensus estimate of...
-
Codexis earnings beat by $0.04, revenue topped estimates
Investing.com - Codexis (NASDAQ: CDXS) reported fourth quarter EPS of $-0.19, $0.04 better than the analyst estimate of $-0.23. Revenue for the quarter came in at $30.4M versus the consensus...
-
Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108
Codexis , Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and Nestlé Health Science, a leader in the science of nutrition, today announced interim results from a Phase 1 study...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 2.15%
Investing.com – U.S. equities were higher at the close on Friday, as gains in the Financials, Healthcare and Consumer Services sectors propelled shares higher. At the close in NYSE, the Dow...
-
After-Hours Stock Movers 03/30: (OEG) (PRG) (CORT) Higher; (PATH) (EXFY) (MASI) Lower (more...)
After-Hours Stock Movers:UiPath Inc. (PATH) 20% LOWER; reported fourth-quarter EPS of $0.05, versus the consensus of $0.03. Revenue for the quarter came in at $289 million versus the...
-
Codexis Gains Premarket As Order Win Prompts New Guidance
By Dhirendra Tripathi Investing.com – Codexis (NASDAQ:CDXS) stock was up 3% in Friday’s premarket trading following a $13.9-million-order win, resulting in the company raising its...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
